EQS-Ad-hoc: voxeljet AG / Key word(s): Capital Increase voxeljet AG Announces Private Placement of Ordinary Shares
19 December 2022 FRIEDBERG, Germany -- voxeljet AG (NASDAQ: VJET) (the "Company", or "voxeljet") management board today approved, with the consent of the supervisory board, an increase in the Company's registered share capital against cash contributions, excluding the subscription rights of existing shareholders, in an amount of EUR 828,943.00 (the “Capital Increase”). The Company partially utilized its authorized capital and resolved to increase its share capital from EUR 8,305,781.00 to EUR 9,134,724.00 by issuing 828,943 new ordinary shares with dividend entitlements beginning with the 2022 financial year ("New Shares"). American Depositary Shares ("ADSs"), each representing one ordinary share, will be issued for the New Shares. All New Shares are being privately placed with Anzu’s industrial technology investment fund. The aggregate placement proceeds amount to USD 1,790,517. The Company intends to use the net issue proceeds for general corporate purposes. This press release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful. Important Additional Information This announcement is neither an advertisement nor a prospectus and does not constitute a recommendation with respect to the securities described in this announcement. The New Shares and related ADSs were offered in a private placement under Section 4(a)(2) under the Securities Act of 1933, as amended (the “Securities Act”), and have not been registered under the Securities Act or any state securities laws or the securities laws of any other jurisdiction. Accordingly, the New Shares and related ADSs may not be offered or sold in the United States, or for the benefit of U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities or blue sky laws. Forward-Looking Statements To the extent this document contains forward-looking statements, such statements are not statements of fact and are made using words such as "expect", "believe", "estimate", "intend", "strive", "assume" and similar expressions. These statements are an expression of the intentions, views or current expectations and assumptions of voxeljet AG and are based on current plans, estimates and forecasts made by voxeljet AG on the basis of its best knowledge, but do not constitute any statement with respect to their future accuracy. You should not place undue reliance on these statements. voxeljet AG cannot provide assurances that the matters described in this press release will be successfully completed or that voxeljet AG will realize the anticipated benefits of any transaction. Forward-looking statements are subject to risks and uncertainties, which are usually difficult to predict and ordinarily not in the domain of influence of voxeljet AG. These risks and other factors are discussed in more detail in the Company’s public filings with the SEC. It should be noted that actual events or developments could materially differ from the events and developments described or included in the forward-looking statements. Statements made herein are as of the date hereof and should not be relied upon as of any subsequent date. The Company disclaims any obligation to update any forward-looking statements except as may be required by law.
19-Dec-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | voxeljet AG |
Paul-Lenz-Str. 1a | |
86316 Friedberg | |
Germany | |
Phone: | +49 821 7483 100 |
Internet: | www.voxeljet.de |
ISIN: | US92912L2060 |
WKN: | A2QBGM |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1517031 |
End of Announcement | EQS News Service |
|
1517031 19-Dec-2022 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.